Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +39.43%
#3 Glidr Glidr +36.87%
#4 Humanity Humanity +27.14%
#5 Codatta Codatta +18.89%
#6 Walrus Walrus +18.20%
#7 Collector Crypt Collector Crypt +18.13%
#8 Provenance Blockchain Provenance Blockchain +17.25%
#9 Enso Enso +16.62%
#10 The Black Bull The Black Bull +14.46%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Lysogene S.A. Lysogene S.A.

Lysogene S.A.

LYS
Rank in Stocks #36618
Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy,... Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy, dedicated to discovering and advancing treatments for children affected by severe neurodegenerative lysosomal storage disorders. Its development pipeline includes LYS-SAF302, which is currently undergoing Phase II/III clinical trials for mucopolysaccharidosis type IIIA (MPS IIIA). Another promising candidate, LYS-GM101, is in Phase I/II development, targeting GM1 gangliosidosis. The company has also forged a research alliance with the Weizmann Institute of Science to pioneer novel adeno-associated virus (AAV) gene therapy approaches for conditions such as neuronopathic Gaucher disease, Parkinson's disease, and other related illnesses. Lysogene S.A. was established in 2009 and is headquartered in Neuilly-sur-Seine, France.
Share Price
$0.30221445
Last synced: 2023-05-22
Market Cap
$2.49M
Change (1 day)
-0.10%
Change (1 year)
0.00%
Country
FR
Trade Lysogene S.A. (LYS)

Category

Healthcare
P/E ratio for Lysogene S.A. (LYS)
P/E ratio as of 2026 TTM: 0
According to Lysogene S.A. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Lysogene S.A. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.